EGFR-positive tumors: the issue of optimal therapy across several lines - memoinOncology
Results for two new third-generation EGFR TKIs
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG) - ScienceDirect
An Early Look at Adjuvant Osimertinib Shows a Dramatic Improvement in Disease-Free Survival - ILCN.org (ILCN/WCLC)
Critical Review of *EGFR*-Mutated NSCLC What We Do and Do Not Know | Published in healthbook TIMES Oncology Hematology
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study | SpringerLink
Efficacy of Metastatic NSCLC – TAGRISSO® (osimertinib) Nurse Center
New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
Why is Tagrisso not reimbursable as 1st-line treatment in Korea? < Hospital < Article - KBR
Patients with advanced non‑small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real‑world data analysis
Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset - Journal of Thoracic Oncology
Efficacy of TAGRISSO® (osimertinib) in Resectable EGFRm NSCLC
EGFR-positive tumors: the issue of optimal therapy across several lines - memoinOncology
Overall survival in patients who received osimertinib in any line... | Download Scientific Diagram
Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study - The Lancet Regional Health –
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
Efficacy of Metastatic NSCLC – TAGRISSO® (osimertinib) Nurse Center
Final overall survival (OS) data from FLAURA trial - YouTube
First-Line Osimertinib in Patients with NSCLC and EGFR Mutation
Dr. Antonio Calles 🫁🚭 on Twitter: "Final OS analysis from FLAURA trial. 🤫 Don't tell @EMA_News Exon21 L858R EGFR mutation doesn't show overall survival benefit from osimertinib. #ESMO19 #LCSM https://t.co/Bp5fg54iTt" / Twitter
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer - ScienceDirect
